Therapy of ocular toxoplasmosis
- 49 Downloads
- 23 Citations
Abstract
We performed a prospective multicentre study to evaluate the efficacy of therapeutic strategies currently used for ocular toxoplasmosis in a large number of patients (n=106). Treatment was given for at least four weeks and consisted of three triple drug combinations: group 1, pyrimethamine, sulphadiazine and corticosteroids (n=29); group 2. clindamycin, sulphadiazine and corticosteroids (n=37); and group 3. cotrimoxazole (trimethoprim and sulphamethoxazole) and corticosteroids (n=8). Patients with peripheral retinal lesions remained without systemic therapy (group 4, n=32). Patients from group 1 received leucovorin 5 mg twice a week.
No difference in the duration of inflammatory activity was observed between the treated and untreated patients or between the separate groups of patients. The most important factor predicting the duration of inflammatory activity was the size of the retinal focus itself, independently of the therapy given (P<0.05).
We showed a reduction in size of the retinal inflammatory focus in 52% of the pyrimethamine patients as compared to 25% of untreated cases. However the most frequent side effects were also associated with pyrimethamine medication and included hematologic complications as thrombocytopenia and leucopenia despite leucovorin medication.
Key words
ocular toxoplasmosis drug therapy pyrimethamine clindamycin cotrimoxazole sulphadiazine corticosteroidsPreview
Unable to display preview. Download preview PDF.
References
- 1.Henderly DE, Genstler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol 1987; 103: 131–136.PubMedGoogle Scholar
- 2.Perkins ES. Ocular toxoplasmosis. Br J Ophthalmol 1973; 57: 1–17.PubMedGoogle Scholar
- 3.O'Connor GR. Toxoplasmosis. In: Freunfelder FT, Roy FH, eds. Current Ocular Therapy. Philadelphia: W.B. Sanders, 1980: 99–101.Google Scholar
- 4.Thiermann E, Apt W, Atias A, Lorca M, Olguin J. A comparative study of some combined treatment regimens in acute toxoplasmosis in mice. Am J Trop Med Hyg 1978; 27: 747–750.PubMedGoogle Scholar
- 5.Harper JS. London WT, Sever JL. Five drug regimens for treatment of acute toxoplasmosis in squirrel monkeys. Am J Trop Med Hyg 1985; 34: 50–57.PubMedGoogle Scholar
- 6.Tate GW, Martin RG. Clindamycin in the treatment of human ocular toxoplasmosis. Canad J Ophthal 1977; 12: 188–195.PubMedGoogle Scholar
- 7.Chandra J, Donaldson EJ. Clindamycin in human ocular toxoplasmosis: a preliminary report. Austr J Ophthal 1978; 6: 135–141.Google Scholar
- 8.Tabbara KF, O'Connor RG. Treatment of ocular toxoplasmosis with clindamycin and sulphadiazine. Ophthalmology 1980; 87: 129–134.PubMedGoogle Scholar
- 9.Ferguson JG. Clindamycin therapy for toxoplasmosis. Ann Ophthalmol 1981; 13: 95–100.PubMedGoogle Scholar
- 10.Lakhanpal V, Schocket SS, Nirankari VS. Clindamycin in the treatment of toxoplasmic retinochoroiditis. Am J Ophthalmol 1983; 95: 605–613.PubMedGoogle Scholar
- 11.Goldstein H. Clindamycin and sulphonamides in the treatment of ocular toxoplasmosis. Acta Ophthalmol 1983; 61: 51–57.Google Scholar
- 12.Norby R, Eilard T, Svedhem A, Lycke E. Treatment of toxoplasmosis with Trimethoprim-Sulphamethoxazole. Scand J Infect Dis 1975; 7: 72–75.Google Scholar
- 13.Williams M, Savage DCL. Acquired toxoplasmosis in children. Arch Dis Child 1978; 53: 829.PubMedGoogle Scholar
- 14.Kijlstra A, Breebaart AC, Baarsma GS et al. Aqueous chamber taps in toxoplasmic chorioretinitis. Doc Ophthalmol 1986; 64: 53–58.CrossRefPubMedGoogle Scholar
- 15.Smith RE, Nozik RA, eds. Toxoplasmic Retinochoroiditis. In: Uveitis, A clinical approach to diagnosis and management, Williams and Wilkins 1989; 128–134.Google Scholar
- 16.Acers TE. Toxoplasmic Retinochoroiditis: A Double Blind Therapeutic Study. Arch Ophthalmol 1964; 71: 58–62.PubMedGoogle Scholar
- 17.Nicholson DH, Wolchok EB. Ocular toxoplasmosis in an adult receiving long-term corticosteroid therapy. Arch Ophthalmol 1976; 94: 248–254.PubMedGoogle Scholar